Clinical Trial Update: Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating administration as a biological adjuvant in clinically-staged, resectable pancreatic adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Snippet

Sponsor: Edward Nelson | Conditions: Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer | Phase 1 | Status: COMPLETED